FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
Purpose
This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilateral mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclerosis (MTS), is safe (frequency of adverse events) and effective (seizure frequency). NRTX-1001 comprises human interneurons that secrete a neurotransmitter, gamma-aminobutyric acid (GABA).
Condition
- Mesial Temporal Lobe Epilepsy
Eligibility
- Eligible Ages
- Between 18 Years and 75 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Male or Female, age ≥18 to 75 2. Focal seizures, clinically defined as unilateral MTLE 3. Has failed to achieve seizure control despite adequate trials of at least 2 ASDs at appropriate doses 4. Currently on stable doses (at least 1 month) of approved ASDs 5. Single seizure focus confirmed within one hippocampus 6. Seizure frequency averages ≥4 per 28-day period, including at least 2 clinical focal seizures per 28-day period with objective manifestations or more severe types, over the 6 months prior to the Screening Visit. 7. Considered (by Investigator) to be a candidate for temporal lobectomy (TL) or Laser Interstitial Thermal Therapy (LITT) following evaluation at a qualified epilepsy surgery program (National Association of Epilepsy Centers [NAEC] Level 4).
Exclusion Criteria
- Epilepsy due to other and/or progressive neurologic disease 2. Evidence of seizure focus outside of the hippocampus or evidence of seizures of non- focal origin. 3. Significant other medical conditions which would impair safe participation 4. History of status epilepticus in the year prior to screening. A history of cluster seizures is permitted. 5. Primary or secondary immunodeficiency 6. Suicide attempts in the past year 7. Severe psychiatric disorders 8. Prior lobectomy or LITT procedure 9. MRI indicating potential malignant lesion 10. Pregnancy, or currently breastfeeding.
Study Design
- Phase
- Phase 1/Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Intervention Model Description
- This is a two-phase study. Phase 1 is an open-label, single arm, sequential dose escalation. Phase 2 is a parallel, randomized, 2-arm, sham controlled study.
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Investigator, Outcomes Assessor)
- Masking Description
- This is a two-phase study. Phase 1 is open-label and unmasked. Phase 2 is blinded with participant, part of investigator team, and outcomes assessor masked to treatment assignment.
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental NRTX-1001 (Phase 1) |
Up to 28 subjects |
|
|
Experimental NRTX-1001 (Phase 2) |
Up to 20 subjects |
|
|
Sham Comparator Sham Comparator(Phase 2) |
Up to 10 subjects. |
|
Recruiting Locations
Phoenix 5308655, Arizona 5551752 85054
Tucson 5318313, Arizona 5551752 85724-5023
Little Rock 4119403, Arkansas 4099753 72205
Los Angeles 5368361, California 5332921 90033
Los Angeles 5368361, California 5332921 90095
Orange 5379513, California 5332921 92868
Palo Alto 5380748, California 5332921 94304
Sacramento 5389489, California 5332921 95817
San Diego 5391811, California 5332921 92037
San Francisco 5391959, California 5332921 94143
Aurora 5412347, Colorado 5417618 80045
Miami 4164138, Florida 4155751 33136
Chicago 4887398, Illinois 4896861 60612
Chicago 4887398, Illinois 4896861 60637
Iowa City 4862034, Iowa 4862182 52242
New Orleans 4335045, Louisiana 4331987 70121
Boston 4930956, Massachusetts 6254926 02215
Detroit 4990729, Michigan 5001836 48201
Omaha 5074472, Nebraska 5073708 68198
New York 5128581, New York 5128638 10016
Syracuse 5140405, New York 5128638 13210
Charlotte 4460243, North Carolina 4482348 28204
Durham 4464368, North Carolina 4482348 27710
Winston-Salem 4499612, North Carolina 4482348 27157
Portland 5746545, Oregon 5744337 97239
Philadelphia 4560349, Pennsylvania 6254927 19107
Houston 4699066, Texas 4736286 77030
Salt Lake City 5780993, Utah 5549030 84108
Seattle 5809844, Washington 5815135 98104
Milwaukee 5263045, Wisconsin 5279468 53226
More Details
- NCT ID
- NCT05135091
- Status
- Recruiting
- Sponsor
- Neurona Therapeutics
Detailed Description
Subjects will undergo a single CT or MRI-guided intracerebral administration of human interneurons that secrete the inhibitory neurotransmitter, gamma-aminobutyric acid (GABA), into the temporal lobe region of the brain where the seizures are thought to arise. NRTX-1001 is intended to suppress the onset and spread of seizures. Safety, tolerability, and effects on reducing seizure frequency and epilepsy disease symptoms will be assessed at quarterly intervals for 2 years after the administration of NRTX-1001. After the two-year period, subjects will be followed with quarterly phone calls and annual visits in years 3 through 5, and then annual visits in years 6 through 15. Subjects will be placed on an immunosuppressant medication regimen for a duration of one year to partially suppress the subjects' immune system to promote the intended long-term persistence of NRTX-1001. This immunosuppressant medication is intended to be discontinued after the first year; however, the NRTX-1001 cells are intended to persist long-term.